newsfilter
← Latest News
GlobeNewswire·

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment Advancing CY3018, a differentiated,